Announcement • Jul 16
Valerio Therapeutics Enters into Binding Term-Sheet with Abivax for Exclusive Global Research and Development Collaboration and Provides Pipeline Update Valerio Therapeutics entered into a binding term-sheet with Abivax, setting out the principal terms of an exclusive worldwide research and development collaboration. The final terms remain subject to the signing of the definitive co-ownership and license agreement. In connection with this collaboration, Valerio Therapeutics and Abivax will work together to identify, design and evaluate next-generation therapeutic candidates for immune-mediated inflammatory diseases, leveraging Abivax’s expertise in this area together with Valerio Therapeutics' targeted technology platforms. The collaboration will include the generation, manufacturing and preclinical evaluation of research candidates. The candidates will be evaluated for their therapeutic potential and may be further developed by Abivax. Under the terms of the binding term-sheet, Valerio Therapeutics will receive an upfront payment up to approximately EUR 2.4 million and would be eligible to receive development and commercial milestone payments, as well as royalties on net sales and sublicensing revenues, subject to the execution of the definitive co-ownership and license agreement and the achievement of specified milestones and other terms. For Valerio Therapeutics, the execution of this binding term-sheet represents an important milestone in the evolution of the Company as a precision RNA therapeutics developer with a growing pipeline. The partnership with Abivax will provide non-dilutive funding to support pipeline advancement, will supplement the existing potential for future milestone and royalty revenues and will reinforce the attractiveness of Valerio Therapeutics’ technology platform to biotech and pharmaceutical partners. This transaction is aligned with Valerio Therapeutics’ strategy of advancing a focused portfolio of wholly owned therapeutic programs while complementing these efforts through partnerships and licensing transactions that leverage its platform capabilities and create additional value creation opportunities. Valerio Therapeutics will provide further updates in due course, including upon signature of the definitive co-ownership and license agreement, in accordance with its obligations under the binding term-sheet and applicable regulatory obligations. Valerio Therapeutics is advancing a pipeline of precision RNA therapeutics focused on diseases where targeted delivery to specific immune cells enables differentiated treatment approaches. The Company’s lead programs have been selected based on a combination of strong disease biology, clear unmet medical need and the ability to leverage Valerio Therapeutics’ proprietary V-Body platform to direct RNA-based payloads to disease-relevant tissue. The proprietary pipeline currently includes the lead program VTX-001 in ankylosing spondylitis, VTX-002 in IgG4-related disease and VTX-003 in oncology. VTX-001 and VTX-002 are next-generation in vivo CAR-T approaches in the immunity & inflammation field and are designed to selectively deplete pathogenic immune-cell populations, while VTX-003 uses a V-Body–oligonucleotide conjugate approach to deliver siRNA to reactivate exhausted T cells in oncology. Valerio Therapeutics’ platform is designed to accelerate discovery and development by enabling rapid generation of tailored V-Bodies, which can be combined with RNA payloads and next-generation lipid nanoparticle technologies across multiple therapeutic modalities. The Company's strategy and pipeline reflect a milestone-driven approach to value inflection, with the ambition to nominate up to two development candidates within 12 to 18 months and to progress at least one program into first-in-human clinical studies within 18 to 24 months. Buy Or Sell Opportunity • Jul 02
Now 50% overvalued after recent price rise Over the last 90 days, the stock has risen 202% to €0.37. The fair value is estimated to be €0.25, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 37%. Announcement • Jun 17
Valerio Therapeutics Société Anonyme Announces Board and Executive Changes Valerio Therapeutics Société anonyme announced the General Meeting approved all resolutions recommended by the Board of Directors, and the appointment of new directors Eric Vivier, Wael Jdey and Gilles Besin and Antoine Barouky will step down from his role as Deputy Chief Executive Officer, effective June 30, 2026. 
